Clinical Trial: CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07808112) titled 'CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation' on Sept. 03.

Brief Summary: This is a randomized, multisite, Phase II study designed to compare the 1-year GVHD-free survival of the control arm (no axatilimab) to the experimental arm (axatilimab) after myeloablative allogeneic HCT.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Graft -Versus-host-disease

Intervention: PROCEDURE: Hematopoietic Cell Transplantation

Subjects will receive a first HLA-matched related or (7/8 or 8/8) unrelated donor myeloabl...